{"nctId":"NCT00288704","briefTitle":"Rilonacept for Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS)","startDateStruct":{"date":"2005-12"},"conditions":["Familial Cold Autoinflammatory Syndrome (FCAS)","Familial Cold Urticaria","Muckle-Wells Syndrome (MWS)","Genetic Diseases, Inborn"],"count":104,"armGroups":[{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]},{"label":"rilonacept 160 mg","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: rilonacept 160 mg"]},{"label":"Open-Label rilonacept 160 mg","type":"OTHER","interventionNames":["Drug: rilonacept 160 mg"]}],"interventions":[{"name":"rilonacept 160 mg","otherNames":["Rilonacept"]},{"name":"Placebo","otherNames":[]},{"name":"rilonacept 160 mg","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Double-blind phases: adults age 18 and above; Open-label extension: Adults and children aged 7 years and older.\n* Was diagnosed with Familial Cold Auto-inflammatory Syndrome (FCAS) or Muckle-Wells Syndrome (MWS) based upon clinical signs and symptoms\n* Had documented mutation in NLRP-3 (Cold Induced Autoinflammatory Syndrome-1 or CIAS1) in subject or relative, and willingness to have a confirmatory genetic (Deoxyribonucleic acid or DNA) test (cheek swab).\n* Was able to understand and comply with study procedures and was able to provide informed consent\n* If female, was not currently pregnant and was willing to use contraception during the study\n\nExclusion Criteria:\n\n* Had evidence of untreated tuberculosis or other conditions/therapies that made the subject inappropriate for this study.","healthyVolunteers":false,"sex":"ALL","minimumAge":"7 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline to Week-6 (Part A) Endpoint in Mean Key Symptom Score (KSS)","description":"The mean Key Symptom Score (KSS --from the validated, patient-administered Daily Health Assessment Form(DHAF)) was the average on a 0-10 scale (0=None, 10=Very Severe) of 5 separate scales -- rash, feeling of fever/chills, joint pain, eye redness/pain, and fatigue). KSS was averaged over two 21-day daily reporting periods (the 3 weeks prior to both baseline and week 6). In part A, a negative change in mean values indicated improvement under treatment with rilonacept in symptoms.\n\nThe DHAF was used because it is a validated instrument to collect subject's self-reported responses.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.4","spread":"1.5"},{"groupId":"OG001","value":"3.1","spread":"1.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.1","spread":"1.6"},{"groupId":"OG001","value":"0.5","spread":"0.5"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.3","spread":"0.7"},{"groupId":"OG001","value":"-2.6","spread":"1.9"}]}]}]},{"type":"PRIMARY","title":"Mean Change in Key Symptom Score (KSS) From Week 15 to Week 24 (During the Randomized Withdrawal Phase or Part B)","description":"The mean Key Symptom Score (KSS --from the validated, patient-administered DHAF) was the average on a 0-10 scale (0=None, 10=Very Severe) of 5 separate scales -- rash, feeling of fever/chills, joint pain, eye redness/pain, and fatigue).\n\nSubjects all received rilonacept 160 mg from week 6 through week 14. At week 15, subjects were re-randomized in a 1:1 ratio between Placebo and rilonacept 160 mg. Subjects baseline period was the 21-day period prior to week 15 randomization.\n\nA positive score indicated a worsening of symptoms versus an active treatment rilonacept baseline period.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.2","spread":"0.4"},{"groupId":"OG001","value":"0.3","spread":"0.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.2","spread":"1.0"},{"groupId":"OG001","value":"0.4","spread":"0.5"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.9","spread":"0.9"},{"groupId":"OG001","value":"0.1","spread":"0.4"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Mean Change From Baseline to Endpoint (Week 6) in Number of Disease Flare Days Per Patient","description":"A Disease flare day was any day where the mean Key Symptom Score (KSS) was greater than 3. The KSS was the average on a 0-10 scale (0=None, 10=Very Severe) of 5 separate scales -- rash, feeling of fever/chills, joint pain, eye redness/pain, and fatigue). KSS was calculated for 21 Day Periods at baseline and at the endpoint (from Weeks 3 - 6). The difference in the number of flares between the two periods was averaged for all subjects.\n\nThe DHAF was used because it is a validated instrument to collect subject's self-reported responses. It was the basis for the KSS and the flare day count.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.2","spread":"6.0"},{"groupId":"OG001","value":"8.6","spread":"7.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.0","spread":"6.1"},{"groupId":"OG001","value":"0.1","spread":"0.5"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.2","spread":"3.6"},{"groupId":"OG001","value":"-8.4","spread":"7.1"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Change From Baseline to Endpoint (Week 6) in Physician's Global Assessment","description":"The Physician's Global Assessment was an evaluation at each visit on a scale of 0=no disease activity to 10=severe disease activity. A negative value in change in Physician's Global Assessment is indicative of an improvement.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.7","spread":"2.0"},{"groupId":"OG001","value":"5.6","spread":"1.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.0","spread":"2.5"},{"groupId":"OG001","value":"1.5","spread":"1.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.2","spread":"2.1"},{"groupId":"OG001","value":"-4.2","spread":"2.4"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Mean Change From Baseline to Endpoint (Week 6) in Patient's Global Assessment","description":"The Patient's Global Assessment was a question on the Daily Health Assessment Form \"Considering all the ways that Familial Cold Autoinflmatory Syndrome (FCAS) /Muckle-Wells Syndrome (MWS) affects you, please rate how you are doing based on the following scale\" 0=very well to 10=very poor. A negative value in change in Patient's Global Assessment is indicative of an improvement.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.1","spread":"2.0"},{"groupId":"OG001","value":"3.6","spread":"2.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.7","spread":"1.8"},{"groupId":"OG001","value":"0.9","spread":"1.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.4","spread":"1.1"},{"groupId":"OG001","value":"-2.7","spread":"2.2"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Median Change From Baseline to Week 6 (Part A) Endpoint in C-Reactive Protein (mg/L)","description":"An abnormal value for CRP was considered \\> 8.4 mg/L.","paramType":"MEDIAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"25.2","spread":"15.7"},{"groupId":"OG001","value":"20.1","spread":"14.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"21.8","spread":"23.9"},{"groupId":"OG001","value":"1.3","spread":"2.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.1","spread":"15.5"},{"groupId":"OG001","value":"-18.4","spread":"14.3"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Median Change From Baseline to Week 6 (Part A) Endpoint in Serum Amyloid A (mg/L)","description":"An abnormal value for SAA was considered \\> 6.4 mg/L.","paramType":"MEDIAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"63.5","spread":"122.3"},{"groupId":"OG001","value":"49.5","spread":"48.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"39.7","spread":"153.7"},{"groupId":"OG001","value":"2.5","spread":"4.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.8","spread":"79.7"},{"groupId":"OG001","value":"-48.5","spread":"48.5"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Number of Subjects With at Least 30% Improvement in Key Symptoms Scores (KSS) From Baseline to Endpoint (Week 6)","description":"The mean Key Symptom Score (KSS --from the validated, patient-administered Daily Health Assessment Form(DHAF)) was the average on a 0-10 scale (0=None, 10=Very Severe) of 5 separate scales -- rash, feeling of fever/chills, joint pain, eye redness/pain, and fatigue).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"22","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Number of Subjects With at Least 50% Improvement in Key Symptoms Scores (KSS) From Baseline to Endpoint (Week 6)","description":"The mean Key Symptom Score (KSS --from the validated, patient-administered Daily Health Assessment Form(DHAF)) was the average on a 0-10 scale (0=None, 10=Very Severe) of 5 separate scales -- rash, feeling of fever/chills, joint pain, eye redness/pain, and fatigue).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"20","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Number of Subjects With at Least 75% Improvement in Key Symptoms Scores (KSS) From Baseline to Endpoint (Week 6)","description":"The mean Key Symptom Score (KSS --from the validated, patient-administered Daily Health Assessment Form(DHAF)) was the average on a 0-10 scale (0=None, 10=Very Severe) of 5 separate scales -- rash, feeling of fever/chills, joint pain, eye redness/pain, and fatigue).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"16","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Summary of Mean Change From Baseline to Open-Label Extension Week 72 in KSS","description":"OLE Week 72 was the last timepoint at which efficacy was measured in the study. 56 of the 101 OLE subjects were included in the analysis.\n\nThe mean Key Symptom Score (KSS --from the validated, patient-administered Daily Health Assessment Form(DHAF)) was the average on a 0-10 scale (0=None, 10=Very Severe) of 5 separate scales -- rash, feeling of fever/chills, joint pain, eye redness/pain, and fatigue).\n\nA negative change in mean values indicated improvement in symptoms.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.6","spread":"1.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.4","spread":"0.5"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.3","spread":"1.6"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Change From Baseline to Open-Label Extension Week 72 in Patient's Global Assessment","description":"The Patient's Global Assessment was a question on the Daily Health Assessment Form \"Considering all the ways that FCAS/MWS affects you, please rate how you are doing based on the following scale\" 0=very well to 10=very poor. A negative value in change in Patient's Global Assessment is indicative of an improvement.\n\nOLE Week 72 was the last timepoint at which efficacy was measured in the study. 56 of the 101 OLE subjects were included in the analysis.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.4","spread":"1.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.4","spread":"0.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.0","spread":"2.0"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Change From Baseline to Open-Label Extension Week 72 in Number of Disease Flare Days","description":"OLE Week 72 was the last timepoint at which efficacy was measured in the study. 56 of the 101 OLE subjects were included in the analysis.\n\nA Disease flare day was any day where the mean Key Symptom Score (KSS) was greater than 3. The mean Key Symptom Score (KSS --from the validated, patient-administered Daily Health Assessment Form(DHAF)) was the average on a 0-10 scale (0=None, 10=Very Severe) of 5 separate scales -- rash, feeling of fever/chills, joint pain, eye redness/pain, and fatigue).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.3","spread":"6.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.6","spread":"3.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.7","spread":"6.9"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":7,"n":104},"commonTop":["Injection Site Reaction","Upper Respiratory Tract Infection","Diarrhea","Nausea","Sinusitis"]}}}